TheraRadar
Clinical-Stage Companies / Jiangsu vcare pharmaceutical technology

Jiangsu vcare pharmaceutical technology

Pre-Approval PRO BETA
26
Total Trials
4
Phase 3
5
Phase 2
5
Recruiting
191
Score

Pipeline by Phase

Phase 3
4
Phase 2
5
Phase 1
17

Therapeutic Focus

Atopic Dermatitis Acute Coronary Syndrome Active Ankylosing Spondylitis Moderate to Severe Atopic Dermatitis Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

Clinical Trials (26)

NCT07172360 Phase 3 RECRUITING

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Started: 12/26/2025

NCT06658353 Phase 3 RECRUITING

Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

Started: 3/17/2025

NCT06723080 Phase 3 RECRUITING

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Started: 12/30/2024

NCT06577519 Phase 3 RECRUITING

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Started: 9/6/2024

NCT07172347 Phase 2 RECRUITING

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Started: 10/31/2025

NCT06891040 Phase 2 COMPLETED

Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

Started: 4/28/2025

NCT05997927 Phase 2 COMPLETED

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Started: 7/20/2023

NCT05814939 Phase 2 COMPLETED

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Started: 4/26/2023

NCT03599284 Phase 2 COMPLETED

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

Started: 8/30/2018

NCT07533851 Phase 1 NOT YET RECRUITING

A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.

Started: 4/30/2026

NCT07329101 Phase 1 COMPLETED

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis

Started: 11/11/2025

NCT07067775 Phase 1 COMPLETED

Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers

Started: 8/5/2025

NCT06974292 Phase 1 COMPLETED

The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers

Started: 5/26/2025

NCT06009094 Phase 1 COMPLETED

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

Started: 7/27/2023

NCT06619951 Phase 1 COMPLETED

A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

Started: 9/18/2024

NCT06529445 Phase 1 COMPLETED

Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects

Started: 7/22/2024

NCT05874622 Phase 1 COMPLETED

A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

Started: 6/12/2023

NCT05162053 Phase 1 COMPLETED

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

Started: 12/9/2021

NCT05528120 Phase 1 COMPLETED

Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

Started: 10/20/2022

NCT05354752 Phase 1 COMPLETED

Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects

Started: 6/18/2022

NCT05138770 Phase 1 COMPLETED

Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects

Started: 11/18/2021

NCT04919551 Phase 1 COMPLETED

A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects

Started: 8/24/2021

NCT04143750 Phase 1 COMPLETED

The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man

Started: 11/11/2019

NCT03942458 Phase 1 COMPLETED

Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19

Started: 4/3/2019

NCT07551570 Phase 1 NOT YET RECRUITING

Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function

Started: 4/30/2026

NCT07551557 Phase 1 NOT YET RECRUITING

Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function

Started: 4/30/2026

Drug Candidates

VC005 Tablets VC005 Placebo group VC005 groups VC005 VC005 tablets VC005 Tablets Placebo Vicagrel Capsules Clopidogrel Tablets [14C]VC005 VC004 Capsules
Activity Status: Active
Last Trial Started: 4/30/2026
Last Trial Ended: 2/28/2026
Trials (12 months): 8
Completed Trials: 18
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.